Dr. Sudhakar Reddy P
Dr. Sudhakar Reddy P
MBBS, MD, DM (Endocrinology)
Consultant Endocrinologist
Qualification / Education:
- MBBS: KMC Warangal 1993-99
- MD: GMC Hyderabad 2001-2004
- Registration No:43581
- DM (Endocrinology): OMC Hyderabad, 2004-07
Experience:
- Worked as Consultant Endocrinologist at Yashoda hospital, Secunderabad from September 2007 to November 2016 (trained DNB students)
- Currently working as a Chief Endocrinologist at Sunshine Hospital, Secunderabad since November 2016.
Expertise:
- Diabetes
- Thyroid
- Bone disorders
Area of Interest:
- Diabetes
- Reproductive Endocrinology
- Bone disorders
- Lipid disorders
- PG TEACHING
Publications:
- Sudhakar R Pendyala, Role of Ultrasounds Thyroid Nodules, International Journal of scientific research, Volume-7, Issue-11, November 2018.
- Baseline characteristics of patients on growth hormone therapy: Expérience of two centers from South India; Babulreddy Hanmayyagari, Mounika Guntaka1, Sunitha Chadalavada2, Voleti Sri Nagesh3, Sudhakar Reddy Pendyala4, Sridevi Patnala5 “Journal of Dr. NTR University of Health Sciences 2015;4(1) 17-20”
- Premature Ovarian Failure in Autoimmune Polyglandular syndrome ” JBCRS_20_12
- Newspaper article on Type-2 diabetics likely to suffer from memory loss, DECCAN CHRONICLE / INDULEKHA ARAKKAL, published: July 26, 2017.
Memberships:
- Endocrine society of India (Membership No. LM 596)
- Indian thyroid society
- Telangana society of endocrinology
- RSSDI
- AACE
Awards and Honours:
- Times health care achievers in Telugu states recognized as The Legend of the year 2018 in Endocrinology
Other:
- Was a part of EDGE trial looking at effects of glucose reductions, CV safety with vildagliptin when added to the current regimen.
- Was part of the DUALLTM VIII Trial, A 104-week study comparing long-term glycemic controls of insulin degludec/liraglutide (DegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus. Trial ID: NN9068-4228
- Was part of NN9536-4373/STEP-1 study where the effect and safety of albiglutide 2.4 mg once weekly in subjects with overweight or obesity was studied
- DUAL VIII Trial: A 104-week study comparing long-term glycemic controls of insulin degludec/liraglutide (DegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus. Trial ID: NN9068-4228
- NN9536-4373: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
- Trail title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)
- Was part of IMPROVE control study
- Was part of IDMPS wave 5 study
